 |
|
|
|
|
|
Exploit Technologies cordially invites you to IP STRATEGY FOR MEDICAL DEVICE PRODUCTS: VentureMD’s Approach on Friday, 3 August 2012. As seating is limited, please register early to avoid disappointment. Our invited speaker is Dr Casey Chan. Dr Casey Chan has over 25 years of experience as an orthopedic surgeon, inventor, researcher and entrepreneur. He has brought a number of innovations from concept to the standard of surgical care, including a vacuum mixing system for total joint replacements and a suture passer for arthroscopic surgery. He is currently an Adjunct Professor at the National University of Singapore (NUS), with appointments at the Department of Orthopaedic Surgery and the Division of Bioengineering, a Fellow of the American Academy of Orthopedic Surgeons and a Fellow of the Canadian Academy of Sport Medicine. His previous experience as the Director of Technology Transfer Office and as the Senior Director of NUS Enterprise at the National University of Singapore (NUS) provides Dr Chan with unique executive and management skills.
Dr Chan is also on the governing board of the Mechanobiology Research Center of Excellence, Singapore and teaches a course on Bioengineering Design for third-year Bioengineering students at NUS. He holds a Master’s Degree of Applied Science in Aerospace Engineering from the University of Toronto, a Doctor of Medicine degree from the University of Toronto, completed orthopedic surgery training at the University of Toronto Residency Program and completed a spine fellowship under Dr Ian MacNab. His research interests lie in the area of tissue engineering and the effects of nanotexture on stem cell differentiations. He has been published in over 50 peer-reviewed publications and currently holds over 40 issued U.S. patents, with more patents pending.
TALK ABSTRACT
A strong IP portfolio cannot be developed overnight. It requires appropriate allocation of resources, including budget, manpower and stakeholders’ interests. Having wide or early IP protection may strain resources that could be better allocated to other operational areas while narrow or late IP protection raises issues of competition and results in weak market control that adversely impacts a company’s business.
VentureMD is a medical device incubator based in the US providing human, financial and intellectual capital to develop and manage start-up medical companies. Integral to VentureMD's product and business development process is a solid IP strategy. This includes:
• Critical involvement from management, technical staff and business development executives
• Understanding the different barriers of entry to Class I, II and III devices
• Making the right decision to file based on product coverage rather than perceived technology performance
This talk aims to provide an insight into the successful internal processes of VentureMD’s IP strategy as well as a better understanding of developing a strong IP portfolio from an investor’s perspective.
ABOUT VentureMD
VentureMD is an angel capital firm and medical device incubator focused on musculoskeletal products. They provide human, financial, and intellectual capital to develop and manage start-up medical device companies around promising ideas. Focusing on developing the best ideas into the best companies, VentureMD serves the areas of orthopedics, spine, dental, arthroscopy and laparoscopy.
Our invited speaker is Douglas Abrams.
Douglas Abrams is the founder and CEO of Expara and Expara IDM Ventures, a business accelerator for interactive and digital media companies. He is also a founding partner of Parallax Capital Management, a fund management company. All three companies are based in Singapore. Prior to coming to Singapore, Douglas managed information technology at J.P Morgan for 14 years. He was Manager of Investment Banking Technology from 1991 and later headed up the Global Markets Internet Marketing division. Douglas graduated from the Annenberg School, University of Pennsylvania with a BA in Communications and received an MBA from The Wharton School. WORKSHOP DETAILS Raising money to fund a new venture involves entrepreneurs and investors in a critically challenging process. In order to scale up successfully, new ventures need to seek funding from venture capitalists or angel investors. Therefore, it is critical for entrepreneurs to have an understanding of venture financing from the investor’s perspective. This workshop aims to provide insights on new venture funding process from the perspectives of both entrepreneurs and investors. Essential skills taught during this workshop include: - Developing a business model for a new venture
- Forecasting revenue, expenses and cash flow
- Raising funding from investors
- Understanding key deal terms and term sheets
This workshop is designed for participants who want to create a scalable business – a business that will grow to a significant size. It will be highly useful for participants who are interested to spin-off or seeking venture funding for their business. The European Collection of Cell Cultures (ECACC) was established in 1984 and since then has been supplying authenticated quality controlled human and animal cell cultures on a global basis. A Culture Collection needs to provide reliable and reproducible cultures as start materials for research to operate successfully. To achieve this, ECACC employs a whole range of authentication techniques on its master and distribution banks which includes STR DNA profiling on all its human cell lines. Every human cell line banked and supplied by ECACC is checked against a database of over 1000 DNA profiles to verify its origin. Mycoplasma contamination can be devastating if introduced to a cell culture facility not to mention the cost to clean up such an outbreak and buy in replacement cultures. Therefore, all ECACC cell lines have been tested negative for mycoplasma by three different methods to ensure its cultures are free from mycoplasma contamination. ECACC has also recently introduced a new method of speciation to replace iso-enzyme analysis, called DNA bar-coding which exploits the variation of mitochondrial DNA amongst different species. In addition to being just good cell culture practice, peer reviewed journals and grant funding bodies are increasingly insisting on quality control and authentication data to support scientific papers and grant applications. All the above methods will be described in detail as to how good cell banking practice ensuring that research projects start off on the right track. | | Bryan Bolton graduated from The University of Salford in 1984 BSc (Hons) in Applied Biology. He went on to do a PhD at Boehringer Mannheim in Germany (now Roche) entitled screening Microorganisms for new restriction enzymes. Following which, he returned to the UK in 1988 and began a career with European Collection of Cell Cultures (ECACC) as a post doc scientist establishing methods for EBV immortalization of B lymphocytes, the Human Genetic Cell Collection and molecular DNA profiling of cell lines. During the following 10 years, he was principal investigator on several UK Medical Research grants concerned with provision of resources for the UK effort as part of the Human Genome Mapping project. In 1997, he obtained a Post Graduate Diploma in Management Studies from the University of Portsmouth which led to taking on a more commercial role within ECACC concerned with sales, marketing and business development. In 2008, he became commercial manager for all four Health Protection Agency Culture Collections which includes National Collection of Type Cultures (NCTC), National Collection of Pathogenic Viruses (NCPV), National Collection of Pathogenic Fungi NCPF as well as ECACC. |
|
Daphne Chia
Intellectual Property Management (IPM) Division
daphne@exploit-tech.com |
| 03 Aug 2012 4:00 pm - 5:00 pm
|
| Creation Theatrette, Matrix Building, Level 4 |
|
|
|
|
|
| |